Table 4 Effect of biopsy on survival for selected clinical and pathological variables
From: Biopsy of breast cancer metastases: patient characteristics and survival
No. Pts. | All Cause Mortality | |||||
|---|---|---|---|---|---|---|
No. | % total | P value | HR (95%CI) | |||
TOTAL | 409 | 331 | 80.9 | |||
Biopsy at recurrence | ||||||
Biopsy | No Bx | 244 | 222 | 91.0 | 1.00 | |
Bx | 165 | 109 | 66.1 | 0.000 | 0.64 (0.51–0.81) | |
HR & HER2at initial diagnosis | ||||||
HR+/HER2+ | No Bx | 38 | 30 | 78.9 | 1.00 | |
Bx | 10 | 6 | 60.0 | 0.499 | 0.74 (0.30–1.79) | |
HR-/HER2- | No Bx | 35 | 33 | 94.3 | 1.00 | |
Bx | 14 | 10 | 71.4 | 0.236 | 0.65 (0.32–1.33) | |
HR-/HER2+ | No Bx | 35 | 33 | 94.3 | 1.00 | |
Bx | 9 | 5 | 55.6 | 0.562 | 0.75 (0.29–1.98) | |
HR+/HER2- | No Bx | 99 | 90 | 90.9 | 1.00 | |
Bx | 74 | 49 | 66.2 | 0.097 | 0.74 (0.52–1.06) | |
HR and/or HER2 missing | No Bx | 37 | 36 | 97.3 | 1.00 | |
Bx | 58 | 39 | 67.2 | 0.001 | 0.45 (0.28–0.71) | |
Site of metastasis at recurrence | ||||||
No liver & lung or brain metastases | No Bx | 202 | 182 | 90.1 | 1.00 | |
Bx | 139 | 86 | 61.9 | 0.001 | 0.63 (0.49–0.82) | |
Liver & lung metastases | No Bx | 17 | 15 | 88.2 | 1.00 | |
Bx | 18 | 17 | 94.4 | 0.539 | 0.80 (0.39–1.63) | |
Brain metastases | No Bx | 25 | 25 | 100.0 | 1.00 | |
Bx | 8 | 6 | 75.0 | 0.196 | 0.55 (0.22–1.36) | |
Age at metastatic recurrence | ||||||
Age <70 years | No Bx | 207 | 189 | 91.3 | 1.00 | |
Bx | 141 | 92 | 65.2 | 0.000 | 0.62 (0.48–0.80) | |
Age >=70 years | No Bx | 37 | 33 | 89.2 | 1.00 | |
Bx | 24 | 17 | 70.8 | 0.587 | 0.85 (0.47–1.54) | |
Stage at initial diagnosis | ||||||
Stage 0-IIA | No Bx | 82 | 71 | 86.6 | 1.00 | |
Bx | 90 | 56 | 62.2 | 0.025 | 0.67 (0.47–0.95) | |
Stage IIB-III | No Bx | 161 | 151 | 93.8 | 1.00 | |
Bx | 71 | 51 | 71.8 | 0.034 | 0.71 (0.51–0.97) | |